TRANSCRIPTOME-BASED BIOMARKERS IN HUMAN OSTEOARTHRITIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。研究人员将收集骨关节炎（OA）和类风湿性关节炎（RA）患者或正常人的血液、DNA、血清蛋白等，以用于后期评估与OA或RA相关的变化。这是由美国国立卫生研究院赞助的一项更大协议的一部分，该协议旨在收集这些样本，希望能够检测到OA或RA活动的合理特定标记物。血液、DNA、pbmc的RNA、血清以及滑液和组织将被收集和储存，并通过微阵列技术或蛋白质组学方法进行分析。目前还没有很好的OA进展或活动的标志物，人们普遍认为，在缺乏血清或其他标志物的情况下，有效的药物治疗很难取得进展。这是美国国立卫生研究院资助的五项研究之一，旨在开发OA疾病活动的生物标志物。此外，由于DNA将可用于可能的遗传分析和血清等蛋白质组学分析，因此也可以进行其他类型的分析。方法：方法简单直接。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The investigators will collect blood, DNA, serum proteins, etc from patients with osteoarthritis (OA) and rheumatoid arthritis (RA) or normals for later evaluation of changes associated with OA or RA. This is part of a larger protocol sponsored by the NIH to collect these samples in hopes that a reasonably specific marker of OA or RA activity can be detected. Blood, DNA, RNA from PBMCs, serum as well as synovial fluid and tissue will be collected and banked and analyzed by microarray technologies or proteomics approaches. At present there are no good markers for progression or activity of OA, and it is generally appreciated that little progress in effective drug therapies can be made in the absence of easy serum or other markers to follow. This is one of five NIH-sponsored studies designed to develop biomarkers for OA disease activity. In addition, because DNA will be available for possible genetic analysis and serum, etc for proteomic analysis, it will be possible to perform other sorts of analysis as well. Approach: The approach is simple and straightforward.